Dolutegravir-based regimen safe and effective for people taking rifampicin for TB
“They’re just making me feel worse”: beliefs about HIV treatment among African and Caribbean people living in the UK
Half of people with HIV can start treatment on same day
Switching to TAF-based PrEP improves kidney and bone markers – but does it raise cardiovascular risk?
Oral cabotegravir and rilpivirine still effective at 312 weeks
Rapid treatment start doesn't benefit all
Ibalizumab monoclonal antibody is effective in real-world use
Do integrase inhibitors increase the risk of diabetes?
Point-of-care viral load testing results in more switches from failing treatment
